Literature DB >> 35654824

Life expectancy and burden of late complications after reduced intensity conditioning allogeneic transplantation.

Adrien Rousseau1, Antoine Capes1, Aurélien Sutra Del Galy1,2, David Michonneau1,2, Marie Robin1, Flore Sicre de Fontbrune1, Aliénor Xhaard1, Camilla Frieri1, Lionel Adès3, Emmanuel Raffoux4, Chantal Himberlin5, Mathilde Baudet6, Régis Peffault de Latour1,2, Gérard Socié7,8.   

Abstract

Reduced intensity conditionings (RIC) before after allogeneic hematopoietic stem cell transplantation (HSCT) allow older or unfit patients of being transplanted, but survival expectancy and burden of late complications are poorly described in this setting. All patients (N = 456) who were alive and relapse-free 2 years after HSCT following RIC were included. Cumulative incidences (CI), standardized incidence, or mortality, ratio (SIR or SMR), and competing risk models were used. The 10-year CIs of relapse and non-relapse mortality incidences were 13.9 and 13.4%, respectively. Seventy-eight patients died, late relapse being the most frequent cause of death leading to a SMR of 6.38 (95% CI, 5.1-8.0; p < 0.001). Among non-relapsing patients (n = 412), 30 died (SMR 4.38; 95% CI, 3.3-5.8: p < 0.001). A total of 37 patients developed 41 SM leading to a 10-year cumulative incidence of 12.9%, and a significant SIR relative to the general population (1.4). Finally, we found high CI of cardiovascular (CVC) and venous thromboembolic complications (VTE) (10-year CI; 15.1% and 11.7%, respectively). Older age was the only significant risk factor for CVC and VTE in multivariable analysis. In conclusion, with life expectancy rate of 70%, late survivors after RIC warrants long-term follow-up and active intervention on averting cardiovascular disease and screening cancers.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Year:  2022        PMID: 35654824     DOI: 10.1038/s41409-022-01715-5

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.174


  40 in total

1.  The future of allogeneic hematopoietic stem cell transplantation: minimizing pain, maximizing gain.

Authors:  M T Little; R Storb
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

2.  Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.

Authors:  S Giralt; P F Thall; I Khouri; X Wang; I Braunschweig; C Ippolitti; D Claxton; M Donato; J Bruton; A Cohen; M Davis; B S Andersson; P Anderlini; J Gajewski; S Kornblau; M Andreeff; D Przepiorka; N T Ueno; J Molldrem; R Champlin
Journal:  Blood       Date:  2001-02-01       Impact factor: 22.113

3.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.

Authors:  S Giralt; E Estey; M Albitar; K van Besien; G Rondón; P Anderlini; S O'Brien; I Khouri; J Gajewski; R Mehra; D Claxton; B Andersson; M Beran; D Przepiorka; C Koller; S Kornblau; M Kørbling; M Keating; H Kantarjian; R Champlin
Journal:  Blood       Date:  1997-06-15       Impact factor: 22.113

4.  Letter to the Editor: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality.

Authors:  A Sutra Del Galy; A Marouf; E Raffoux; M Robin; D Michonneau; M Sébert; F Sicre de Fontebrune; A Xhaard; E Lengline; R Itzykson; C Frieri; H Dombret; P Fenaux; R Peffault de Latour; L Adès; G Socié
Journal:  Leukemia       Date:  2020-07-30       Impact factor: 11.528

5.  Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry.

Authors:  G Socié; J V Stone; J R Wingard; D Weisdorf; P J Henslee-Downey; C Bredeson; J Y Cahn; J R Passweg; P A Rowlings; H C Schouten; H J Kolb; J P Klein
Journal:  N Engl J Med       Date:  1999-07-01       Impact factor: 91.245

6.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.

Authors:  P A McSweeney; D Niederwieser; J A Shizuru; B M Sandmaier; A J Molina; D G Maloney; T R Chauncey; T A Gooley; U Hegenbart; R A Nash; J Radich; J L Wagner; S Minor; F R Appelbaum; W I Bensinger; E Bryant; M E Flowers; G E Georges; F C Grumet; H P Kiem; B Torok-Storb; C Yu; K G Blume; R F Storb
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

7.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.

Authors:  S Slavin; A Nagler; E Naparstek; Y Kapelushnik; M Aker; G Cividalli; G Varadi; M Kirschbaum; A Ackerstein; S Samuel; A Amar; C Brautbar; O Ben-Tal; A Eldor; R Or
Journal:  Blood       Date:  1998-02-01       Impact factor: 22.113

8.  Reduced mortality after allogeneic hematopoietic-cell transplantation.

Authors:  Ted A Gooley; Jason W Chien; Steven A Pergam; Sangeeta Hingorani; Mohamed L Sorror; Michael Boeckh; Paul J Martin; Brenda M Sandmaier; Kieren A Marr; Frederick R Appelbaum; Rainer Storb; George B McDonald
Journal:  N Engl J Med       Date:  2010-11-25       Impact factor: 91.245

9.  Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey.

Authors:  D Niederwieser; H Baldomero; J Szer; M Gratwohl; M Aljurf; Y Atsuta; L F Bouzas; D Confer; H Greinix; M Horowitz; M Iida; J Lipton; M Mohty; N Novitzky; J Nunez; J Passweg; M C Pasquini; Y Kodera; J Apperley; A Seber; A Gratwohl
Journal:  Bone Marrow Transplant       Date:  2016-02-22       Impact factor: 5.483

10.  Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years.

Authors:  Jakob R Passweg; Helen Baldomero; Christian Chabannon; Grzegorz W Basak; Rafael de la Cámara; Selim Corbacioglu; Harry Dolstra; Rafael Duarte; Bertram Glass; Raffaella Greco; Arjan C Lankester; Mohamad Mohty; Régis Peffault de Latour; John A Snowden; Ibrahim Yakoub-Agha; Nicolaus Kröger
Journal:  Bone Marrow Transplant       Date:  2021-02-23       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.